Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02609776 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Study acronym: CHRYSALIS
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 117 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC Completion pushed from Dec 31, 2026 to Dec 31, 2027 · Eligibility criteria expanded, about 11 words Show 2 more changesShow less
    • Completion pushed from Dec 31, 2026 to Dec 31, 2027
    • Eligibility criteria expanded, about 11 words
  2. 9 versions Re-verified since Oct 9, 2025, no change to tracked fieldsv108-v116
  3. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026v107
  4. Re-verified, no change to tracked fieldsv106
  5. Primary completion date: Jan 31, 2024 to Dec 31, 2025v105
Show 37 earlier versionsHide 37 earlier versions
  1. Completion date: Jun 30, 2025 to Dec 31, 2025v104
  2. 14 versions Re-verified since Apr 23, 2024, no change to tracked fieldsv90-v103
  3. Primary completion date changed from estimate of Jan 4, 2024 to Jan 31, 2024 Completion date: Dec 31, 2024 to Jun 30, 2025 · Study sites revised (69)v89 Show 2 more changesShow less
    • Completion date: Dec 31, 2024 to Jun 30, 2025
    • Study sites revised (69)

    See this version in full on ClinicalTrials.gov ↗

  4. Re-verified, no change to tracked fieldsv88
  5. Completion date: Jan 30, 2024 to Dec 31, 2024v87
  6. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 780 to confirmed 751 · Study sites: 90 to 69 · Completion date: Jan 26, 2024 to Jan 30, 2024v86 Show 3 more changesShow less
    • Enrollment target: estimated 780 to confirmed 751
    • Study sites: 90 to 69
    • Completion date: Jan 26, 2024 to Jan 30, 2024
  7. Site details revised at 2 of 90 sitesv85
  8. Site details revised at 5 of 90 sitesv84
  9. Site details revised at 1 of 90 sitesv83
  10. Site details revised at 4 of 90 sitesv82
  11. Study sites revised (90)v81 See this version in full on ClinicalTrials.gov ↗
  12. Site details revised at 1 of 90 sitesv80
  13. Re-verified, no change to tracked fieldsv79
  14. Study sites: 101 to 90v78
  15. Study sites revised (101)v77 See this version in full on ClinicalTrials.gov ↗
  16. Completion date: Jul 31, 2024 to Jan 26, 2024v76
  17. Completion date: Jan 26, 2024 to Jul 31, 2024 Study sites revised (101)v75 Show 1 more changeShow less
    • Study sites revised (101)

    See this version in full on ClinicalTrials.gov ↗

  18. 3 versions Re-verified since Oct 12, 2022, no change to tracked fieldsv72-v74
  19. Study Status, Outcome Measures, Eligibilityv71
  20. Site details revised at 1 of 101 sitesv70
  21. Site details revised at 1 of 101 sitesv69
  22. Completion date: Jan 4, 2024 to Jan 26, 2024v68
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).
Trial Details
NCT Number NCT02609776
Lead Sponsor Janssen Research & Development, LLC
Conditions Non-Small-Cell Lung Cancer
Enrollment 751 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov